Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Natura:	Articolo
Lingua:	English
Pubblicazione:	Elsevier 2020-10-01
Serie:	World Allergy Organization Journal
Soggetti:	Severe asthma Biologics Oral corticosteroids Real-life Registr
Accesso online:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Documenti analoghi

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
di: Claudia Crimi, et al.
Pubblicazione: (2023-11-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
di: Giorgio Walter Canonica, et al.
Pubblicazione: (2020-08-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
di: Carla Rognoni, et al.
Pubblicazione: (2023-06-01)

Asthma severity: the patient’s point of view
di: Gabriella Guarnieri, et al.
Pubblicazione: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
di: Giovanna Elisiana Carpagnano, et al.
Pubblicazione: (2023-10-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
di: Diego Bagnasco, et al.
Pubblicazione: (2020-08-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
di: Diego Bagnasco, et al.
Pubblicazione: (2021-02-01)

Severe asthma: One disease and multiple definitions
di: Diego Bagnasco, MD, PhD, et al.
Pubblicazione: (2021-11-01)

Critical evaluation of asthma biomarkers in clinical practice
di: Giuseppe Guida, et al.
Pubblicazione: (2022-10-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
di: Paolo Solidoro, et al.
Pubblicazione: (2022-01-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
di: Marco Caminati, MD, et al.
Pubblicazione: (2024-08-01)

Phenotype overlap in the natural history of asthma
di: Fabio L.M. Ricciardolo, et al.
Pubblicazione: (2023-05-01)

Minimal clinically important difference for asthma endpoints: an expert consensus report
di: Matteo Bonini, et al.
Pubblicazione: (2020-06-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
di: Diego Bagnasco, et al.
Pubblicazione: (2023-08-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
di: Giorgio Walter Canonica, et al.
Pubblicazione: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
di: Giorgio Walter Canonica, MD, et al.
Pubblicazione: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
di: Francesco Menzella, et al.
Pubblicazione: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
di: Alberto Papi, et al.
Pubblicazione: (2020-08-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
di: Giulia Scioscia, et al.
Pubblicazione: (2020-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
di: Diego Bagnasco, et al.
Pubblicazione: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
di: Dejan Radovanovic, et al.
Pubblicazione: (2017-05-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
di: Corrado Pelaia, et al.
Pubblicazione: (2023-03-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
di: Francesca Bertolini, et al.
Pubblicazione: (2025-02-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
di: Dejan Radovanovic, et al.
Pubblicazione: (2017-06-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
di: Erminia Ridolo, et al.
Pubblicazione: (2020-10-01)

Brittle asthma
di: O. Toungoussova, et al.
Pubblicazione: (2016-02-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
di: Alessandra Vultaggio, et al.
Pubblicazione: (2023-05-01)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
di: Lacedonia D, et al.
Pubblicazione: (2017-06-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
di: Giovanna Elisiana Carpagnano, et al.
Pubblicazione: (2021-03-01)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
di: G. Senna, et al.
Pubblicazione: (2017-04-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
di: Maria D'Amato, et al.
Pubblicazione: (2022-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
di: Paolo Solidoro, et al.
Pubblicazione: (2019-04-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
di: Francesco Menzella, et al.
Pubblicazione: (2016-12-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
di: Carlo Lombardi, et al.
Pubblicazione: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
di: F.G. Salerno, et al.
Pubblicazione: (2016-01-01)

Alexithymia and asthma: a systematic review
di: Orlando Silvestro, et al.
Pubblicazione: (2023-08-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
di: Carlo Lombardi, et al.
Pubblicazione: (2024-07-01)

“Characteristics of patients admitted to emergency department for asthma attack: a real-LIFE study”
di: Laura Losappio, et al.
Pubblicazione: (2019-06-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
di: Corrado Pelaia, et al.
Pubblicazione: (2019-12-01)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
di: Paolo Montuschi
Pubblicazione: (2010-06-01)